Paratek Pharmaceuticals, Inc.

Acetylon Pharmaceuticals, Inc.

Verastem, Inc.

Warner Chilcott Company, LLC

Almirall, LLC

Allergan Pharmaceuticals International Limited

Farzaneh Seyedi

John Henry Van Duzer

Sean M Johnston

Tadeusz Warchol

Giuseppe Motta

Mark Grier

Catherine Coulter

Gui Liu

Meinrad Brenner

Giovanni Palombi

Eugenio Castelli

Ruiliang Lu

Shaozhi Huang

William Paul Armstrong

Gajanan Joshi

Solid forms of a dual RAF/MEK inhibitor, pharmaceutical compositions thereof, oral dosage forms thereof, and methods of treating cancer are described herein. Also provided herein are processes for preparing solid forms of a dual RAF/MEK inhibitor and pharmaceutical compositions and oral dosage forms thereof.

Solid forms of a dual RAF/MEK inhibitor

The described invention relates to sarecycline, related compounds, intermediates and salts thereof and processes for preparing the same.

Process for making sarecycline hydrochloride

This disclosure provides solid forms of 2-((2-chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide, and methods of manufacturing and using these forms.

Crystalline forms of a histone deacetylase inhibitor

The present invention relates to methods and intermediates useful for the synthesis of protein deacetylase inhibitors.

Methods of making protein deacetylase inhibitors

Methods of synthesizing substituted tetracycline compounds are provided.

Methods for synthesizing substituted tetracycline compounds

A crystalline mono hydrochloride salt of (4S,4aS,5aR,12aS)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide is disclosed having improved stability. In addition, a crystalline mono mesylate salt and crystalline mono sulfate salt of (4S,4aS,5aR,12aS)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide are also disclosed having improved stability. A pharmaceutical composition containing the crystalline salts and methods of treating inflammatory skin disorders and bacterial infections comprising administering the crystalline salts are also disclosed.

Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same

Growing community of inventors

Mansfield, MA, United States of America

Farzaneh Seyedi